<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-461" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Imiquimod</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nanda</surname>
            <given-names>Japbani</given-names>
          </name>
          <aff>Renaissance School of Medicine at Stony Brook University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bermudez</surname>
            <given-names>Rene</given-names>
          </name>
          <aff>Sampson Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Japbani Nanda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rene Bermudez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-461.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Imiquimod is a medication used to manage and treat anogenital warts, superficial basal cell carcinomas, and actinic keratoses. It is in the immune modulator class of drugs. This activity describes the indications, action, and contraindications for imiquimod as a valuable agent in treating anogenital warts, superficial basal cell carcinomas, and actinic keratoses. In addition, this activity will highlight the mechanism of action, adverse event profile, and other key factors, such as toxicity and monitoring, pertinent for members of the healthcare team in the management of patients with anogenital warts, superficial basal cell carcinomas, and actinic keratoses.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications of imiquimod.</p></list-item><list-item><p>Identify the adverse effects of imiquimod.</p></list-item><list-item><p>Review the mechanism of action of imiquimod.</p></list-item><list-item><p>Summarize the importance of improving care coordination amongst the interprofessional team to improve outcomes for patients receiving imiquimod.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=461">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-461.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Imiquimod is FDA-approved for the treatment of external anogenital warts, actinic keratoses, and superficial basal cell carcinomas. Imiquimod&#x02019;s 5% cream formulation resulted in a statistically significant improvement in treatment effectiveness for external anogenital warts compared with a vehicle cream.<xref ref-type="bibr" rid="article-461.r1">[1]</xref>&#x000a0;A 3.75% imiquimod cream formulation can also be used to treat external anogenital warts with a shorter duration of treatment.<xref ref-type="bibr" rid="article-461.r2">[2]</xref>&#x000a0;Moreover, 2.5%, 3.75%, or 5% imiquimod creams are effective for treating multiple actinic keratoses in the setting of field cancerization.<xref ref-type="bibr" rid="article-461.r3">[3]</xref><xref ref-type="bibr" rid="article-461.r4">[4]</xref>&#x000a0;For treating superficial basal cell carcinoma, 5% imiquimod was shown to be effective in achieving clinical and histological clearance.<xref ref-type="bibr" rid="article-461.r5">[5]</xref>&#x000a0;Topical imiquimod can treat superficial basal cell carcinoma on low-risk sites, thus excluding the high-risk H-zone of the face, which includes the nose, temples, and eyebrows.<xref ref-type="bibr" rid="article-461.r6">[6]</xref>&#x000a0;Possible application sites to treat superficial basal cell carcinoma include the neck, limbs, or trunk.<xref ref-type="bibr" rid="article-461.r5">[5]</xref>&#x000a0;Although the success rate at five years was inferior in those treated with topical imiquimod for basal cell carcinoma than in those treated with excision, imiquimod&#x02019;s 82.5% 5-year success rate is still of benefit due to a long-term response that may, in fact, be preferred in patients who refuse or cannot undergo surgery.<xref ref-type="bibr" rid="article-461.r6">[6]</xref>&#x000a0;Researchers have studied many non-FDA-approved uses for imiquimod, including but not limited to its use to treat recurrent herpes simplex virus infection, squamous cell carcinoma in situ, and melanoma in situ.<xref ref-type="bibr" rid="article-461.r7">[7]</xref><xref ref-type="bibr" rid="article-461.r8">[8]</xref><xref ref-type="bibr" rid="article-461.r9">[9]</xref></p>
      </sec>
      <sec id="article-461.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Imiquimod is an immune response modifier of the imidazoquinolinamines drug class that induces the production of various cytokines, such as Interferon-alpha, Interferon-gamma, tumor necrosis factor-alpha, interleukin-1, interleukin-6, and interleukin-8.<xref ref-type="bibr" rid="article-461.r10">[10]</xref><xref ref-type="bibr" rid="article-461.r11">[11]</xref>&#x000a0;Imiquimod activates the innate and adaptive immune responses via binding to Toll-like receptor 7 and activation of nuclear factor kappa-B with the resultant cytokine release and recruitment of plasmacytoid predendritic cells to the site of medication application with subsequent release of Interferon-alpha and a Th1 response.<xref ref-type="bibr" rid="article-461.r12">[12]</xref><xref ref-type="bibr" rid="article-461.r13">[13]</xref><xref ref-type="bibr" rid="article-461.r14">[14]</xref><xref ref-type="bibr" rid="article-461.r15">[15]</xref>&#x000a0;In addition to its anti-viral activity, imiquimod induces apoptosis of skin cancer cells and has demonstrated anti-tumoral activity.<xref ref-type="bibr" rid="article-461.r16">[16]</xref></p>
      </sec>
      <sec id="article-461.s4" sec-type="Administration">
        <title>Administration</title>
        <p>To treat external anogenital warts, topical 5% imiquimod cream is applied to clean, dry skin overnight by rubbing in the medication completely and leaving the cream for approximately 6&#x000a0;to 10 hours on alternating days three times per week a maximum of 16 weeks or until warts have cleared.<xref ref-type="bibr" rid="article-461.r1">[1]</xref>&#x000a0;When using 3.75% imiquimod cream to treat external anogenital warts, the patient should apply a thin layer overnight once every day for a maximum of 8 weeks or until warts have cleared.<xref ref-type="bibr" rid="article-461.r2">[2]</xref>&#x000a0;The patient washes the cream off after overnight application.<xref ref-type="bibr" rid="article-461.r1">[1]</xref><xref ref-type="bibr" rid="article-461.r2">[2]</xref>&#x000a0;</p>
        <p>For the treatment of actinic keratoses, 5% imiquimod cream should be applied topically to either the face or scalp to a maximum area of 25 cm^2 once a day, twice weekly over 16 weeks.<xref ref-type="bibr" rid="article-461.r17">[17]</xref>&#x000a0;To treat the entire face or the balding scalp over a shorter treatment period, 2.5% or 3.75% imiquimod cream can be applied as a thin layer once per day overnight for approximately 8 hours for two weeks, followed by&#x000a0;a treatment-free period for&#x000a0;two weeks, and then a subsequent two weeks of treatment.<xref ref-type="bibr" rid="article-461.r4">[4]</xref>&#x000a0;The patient should wash the cream off after overnight application.<xref ref-type="bibr" rid="article-461.r4">[4]</xref>&#x000a0;</p>
        <p>For the treatment of superficial basal cell carcinoma, rub 5% imiquimod cream into a biopsy-confirmed superficial basal cell carcinoma with a maximum lesion diameter of 2 cm and the region 1 cm around the lesion.<xref ref-type="bibr" rid="article-461.r5">[5]</xref> The cream should be applied for a minimum of 8 hours overnight, followed by removal by washing with soap and water.<xref ref-type="bibr" rid="article-461.r5">[5]</xref>&#x000a0;The cream should be applied once per day for 5 days per week over six weeks.<xref ref-type="bibr" rid="article-461.r5">[5]</xref></p>
      </sec>
      <sec id="article-461.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Reported side effects of 5% imiquimod cream, when used to treat external anogenital warts, are often mild and include erythema, edema, erosion, excoriation, induration, or scabbing.<xref ref-type="bibr" rid="article-461.r1">[1]</xref>&#x000a0;Patients have also reported pain, pruritus, and irritation at the site of application or local cutaneous edema or erythema with the use of topical 2.5% or 3.75% imiquimod creams to treat external anogenital warts.<xref ref-type="bibr" rid="article-461.r2">[2]</xref>&#x000a0;When used to treat actinic keratoses, reported local adverse effects of imiquimod cream include erythema, flaking, scabbing, edema, weeping, and erosion, but the presence of these reactions correlates with improved lesion clearance.<xref ref-type="bibr" rid="article-461.r18">[18]</xref>&#x000a0;Less common systemic adverse effects when 5% imiquimod cream was applied to the scalp, face, or upper extremity to treat actinic keratosis included flu-like symptoms, headache, fever, anorexia, somnolence, fatigue, nausea, myalgia, and diarrhea.<xref ref-type="bibr" rid="article-461.r19">[19]</xref>&#x000a0;When applied for the treatment of superficial basal cell carcinoma, adverse effects include pruritus, burning, and pain at the application site and uncommon upper respiratory tract infections, back pain, or sinusitis.<xref ref-type="bibr" rid="article-461.r5">[5]</xref>&#x000a0;Application site reactions usually do not result in treatment withdrawal due to their frequent lack of severity.<xref ref-type="bibr" rid="article-461.r6">[6]</xref></p>
      </sec>
      <sec id="article-461.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Available data are limited regarding the use of imiquimod during pregnancy, and therefore, its use in this setting is not currently recommended.<xref ref-type="bibr" rid="article-461.r20">[20]</xref></p>
      </sec>
      <sec id="article-461.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>During treatment, the response requires assessment to check for clearance of external anogenital warts or actinic keratoses and decreased size or resolution of superficial basal cell carcinoma. Additionally, application site reactions and local cutaneous adverse effects may occur, and patients should have ongoing monitoring for these developments, which may also be indicative of treatment response.<xref ref-type="bibr" rid="article-461.r18">[18]</xref><xref ref-type="bibr" rid="article-461.r5">[5]</xref><xref ref-type="bibr" rid="article-461.r2">[2]</xref>&#x000a0;Percutaneous absorption of topical imiquimod and serum concentrations of the medication are limited.<xref ref-type="bibr" rid="article-461.r21">[21]</xref><xref ref-type="bibr" rid="article-461.r19">[19]</xref>&#x000a0;Systemic adverse effects are typically mild and include fatigue, flu-like symptoms, and headache.&#x000a0;Imiquimod is excreted in the urine.<xref ref-type="bibr" rid="article-461.r19">[19]</xref></p>
      </sec>
      <sec id="article-461.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>While most side effects of topical imiquimod use are mild, there are reports of severe local or systemic adverse effects associated with topical imiquimod use, in which case the prescriber may need to halt treatment.<xref ref-type="bibr" rid="article-461.r22">[22]</xref><xref ref-type="bibr" rid="article-461.r23">[23]</xref>&#x000a0;For patients with autoimmune conditions, the application of imiquimod over large areas of the body should prompt caution, given the potential for a systemic immune response.<xref ref-type="bibr" rid="article-461.r22">[22]</xref></p>
      </sec>
      <sec id="article-461.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional team of clinicians is needed to coordinate the care of patients with external anogenital warts, actinic keratoses, or superficial basal cell carcinomas. Patients with external anogenital warts may first present to a clinician in the fields of primary care, pediatrics, family medicine, dermatology, internal medicine, obstetrics, and gynecology, or urology. Similarly, patients with actinic keratoses or superficial basal cell carcinomas may first present to health care professionals within the fields of internal medicine, primary care, family medicine, or dermatology. Primary care, family medicine, and internal medicine clinicians may refer patients to dermatologists and/or plastic surgeons to manage actinic keratoses or basal cell carcinomas.</p>
        <p>Patients must be instructed on the appropriate application of topical imiquimod cream to ensure safety and optimal treatment results. Nurses, physicians, and physician assistants can help ensure appropriate medication usage by providing written and verbal instructions to patients and/or caregivers. Pharmacists can also play a role by clarifying application instructions if necessary. Members of the healthcare team should also monitor for appropriate treatment response or side effects due to topical imiquimod.<xref ref-type="bibr" rid="article-461.r20">[20]</xref>&#x000a0;[Level 5]</p>
        <p>Patients with external anogenital warts should undergo testing for other sexually transmitted diseases.&#x000a0;They should let current sexual partners know about a diagnosis of anogenital warts because the causative agent, human papillomavirus, can be transmitted sexually and because their partners may wish to undergo testing for sexually transmitted diseases or examination for anogenital warts. Patients should also receive counsel to avoid sexual activity with any new sexual partners while anogenital warts are still present.&#x000a0;Condom use and safe sexual practices should be encouraged, although condom use may not entirely prevent the transmission of human papillomavirus if uncovered areas are also infected. Although the human papillomavirus vaccine will not treat existing external anogenital warts, it may merit consideration to protect against oncogenic types of human papillomavirus.<xref ref-type="bibr" rid="article-461.r20">[20]</xref>&#x000a0;[Level 5]&#x000a0;The coordination of care amongst a team of healthcare professionals is essential to achieve improved patient outcomes.</p>
      </sec>
      <sec id="article-461.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=461">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/461/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=461">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-461.s11">
        <title>References</title>
        <ref id="article-461.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ferenczy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eron</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Hougham</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Schmitt</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.</article-title>
            <source>Arch Dermatol</source>
            <year>1998</year>
            <month>Jan</month>
            <volume>134</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">9449906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ferris</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Martens</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Fife</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Tyring</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ault</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Trofatter</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies.</article-title>
            <source>Infect Dis Obstet Gynecol</source>
            <year>2011</year>
            <volume>2011</volume>
            <fpage>806105</fpage>
            <pub-id pub-id-type="pmid">21876641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Paquet</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villanueva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brintnell</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Interventions for actinic keratoses.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2012</year>
            <month>Dec</month>
            <day>12</day>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>CD004415</fpage>
            <pub-id pub-id-type="pmid">23235610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swanson</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Abramovits</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kulp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rigel</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>582</fpage>
            <page-range>582-90</page-range>
            <pub-id pub-id-type="pmid">20133013</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geisse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Caro</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lindholm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Golitz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Stampone</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2004</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>722</fpage>
            <page-range>722-33</page-range>
            <pub-id pub-id-type="pmid">15097956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Bath-Hextall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ozolins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Colver</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Perkins</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PSJ</given-names>
              </name>
              <collab>Surgery Versus Imiquimod for Nodular and Superficial Basal Cell Carcinoma (SINS) Study Group</collab>
            </person-group>
            <article-title>Surgery Versus 5% Imiquimod for Nodular&#x000a0;and Superficial Basal Cell Carcinoma: 5-Year Results of the SINS&#x000a0;Randomized Controlled Trial.</article-title>
            <source>J Invest Dermatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>137</volume>
            <issue>3</issue>
            <fpage>614</fpage>
            <page-range>614-619</page-range>
            <pub-id pub-id-type="pmid">27932240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Spruance</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2005</year>
            <month>Sep</month>
            <day>15</day>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>808</fpage>
            <page-range>808-14</page-range>
            <pub-id pub-id-type="pmid">16107978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Goodwin</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chawla</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laidler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Price</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Finlay</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Motley</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>54</volume>
            <issue>6</issue>
            <fpage>1025</fpage>
            <page-range>1025-32</page-range>
            <pub-id pub-id-type="pmid">16713457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kirtschig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Meurs</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>van Doorn</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>95</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-5</page-range>
            <pub-id pub-id-type="pmid">24696093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mausberg</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kieseier</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Hofstetter</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Induction of pro-inflammatory cytokine production in thymocytes by the immune response modifiers Imiquimod and Gardiquimod&#x02122;.</article-title>
            <source>Int Immunopharmacol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>427</fpage>
            <page-range>427-31</page-range>
            <pub-id pub-id-type="pmid">23867290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weeks</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro.</article-title>
            <source>J Interferon Res</source>
            <year>1994</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-5</page-range>
            <pub-id pub-id-type="pmid">8077768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hemmi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kaisho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sanjo</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hoshino</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Horiuchi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tomizawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Akira</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway.</article-title>
            <source>Nat Immunol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>3</volume>
            <issue>2</issue>
            <fpage>196</fpage>
            <page-range>196-200</page-range>
            <pub-id pub-id-type="pmid">11812998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urosevic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dummer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Conrad</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beyeler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laine</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burg</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gilliet</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2005</year>
            <month>Aug</month>
            <day>03</day>
            <volume>97</volume>
            <issue>15</issue>
            <fpage>1143</fpage>
            <page-range>1143-53</page-range>
            <pub-id pub-id-type="pmid">16077073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Megyeri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Rosztoczy</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Raj</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Tomai</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pitha</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Stimulation of interferon and cytokine gene expression by imiquimod and stimulation by Sendai virus utilize similar signal transduction pathways.</article-title>
            <source>Mol Cell Biol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>2207</fpage>
            <page-range>2207-18</page-range>
            <pub-id pub-id-type="pmid">7534379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Amakawa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kaisho</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hemmi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tajima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Uehira</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tomizawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akira</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fukuhara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets.</article-title>
            <source>J Exp Med</source>
            <year>2002</year>
            <month>Jun</month>
            <day>03</day>
            <volume>195</volume>
            <issue>11</issue>
            <fpage>1507</fpage>
            <page-range>1507-12</page-range>
            <pub-id pub-id-type="pmid">12045249</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bong</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Drewniok</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Herz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geilen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Reifenberger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benninghoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Slade</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Gollnick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;n</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2003</year>
            <month>Aug</month>
            <day>06</day>
            <volume>95</volume>
            <issue>15</issue>
            <fpage>1138</fpage>
            <page-range>1138-49</page-range>
            <pub-id pub-id-type="pmid">12902443</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dinehart</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Whiting</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Tawfik</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jorizzo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2004</year>
            <month>May</month>
            <volume>50</volume>
            <issue>5</issue>
            <fpage>714</fpage>
            <page-range>714-21</page-range>
            <pub-id pub-id-type="pmid">15097955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadley</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Derry</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Imiquimod for actinic keratosis: systematic review and meta-analysis.</article-title>
            <source>J Invest Dermatol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>126</volume>
            <issue>6</issue>
            <fpage>1251</fpage>
            <page-range>1251-5</page-range>
            <pub-id pub-id-type="pmid">16557235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harrison</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Skinner</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Marbury</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kurup</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McKane</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms.</article-title>
            <source>Arch Dermatol Res</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>296</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-11</page-range>
            <pub-id pub-id-type="pmid">15083310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Workowski</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Bolan</surname>
                <given-names>GA</given-names>
              </name>
              <collab>Centers for Disease Control and Prevention</collab>
            </person-group>
            <article-title>Sexually transmitted diseases treatment guidelines, 2015.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2015</year>
            <month>Jun</month>
            <day>05</day>
            <volume>64</volume>
            <issue>RR-03</issue>
            <fpage>1</fpage>
            <page-range>1-137</page-range>
            <pub-id pub-id-type="pmid">26042815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fein</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of imiquimod 3.75% cream applied daily for 3 weeks to actinic keratoses on the face and/or balding scalp.</article-title>
            <source>Arch Dermatol Res</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>302</volume>
            <issue>7</issue>
            <fpage>539</fpage>
            <page-range>539-44</page-range>
            <pub-id pub-id-type="pmid">20204654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Narang</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation.</article-title>
            <source>Sex Transm Infect</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>432</fpage>
            <pub-id pub-id-type="pmid">21606474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-461.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heikkinen</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Susitaival</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Severe systemic reaction to topical imiquimod.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>91</volume>
            <issue>5</issue>
            <fpage>594</fpage>
            <page-range>594-5</page-range>
            <pub-id pub-id-type="pmid">21629973</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
